Acitrom (Acenocoumarol)-Induced Skin Necrosis: Clinical Presentation
Yes, acitrom-induced skin necrosis lesions are characteristically painful and present with surrounding erythema and well-demarcated borders with induration. This is a rare but serious thrombotic complication that requires immediate recognition and management.
Clinical Features
The presentation follows a predictable pattern that typically manifests between days 3-8 of therapy 1:
Early Symptoms
- Pain and paresthesia in the affected area, often the first warning sign 2
- Sensation of tension in regions with abundant subcutaneous fat 2
- Erythematous flush that appears suddenly in the affected region 2
Progressive Lesion Characteristics
- Well-demarcated borders with clear lines of demarcation between affected and normal tissue 3
- Painful pink or magenta colored skin lesions initially 3
- Surrounding erythema that progresses to petechiae 4
- Induration of the borders and surrounding tissue 5
- Evolution to sharply demarcated ecchymosis, bullae formation, and ultimately gangrenous necrosis 6
Pathophysiology
The lesions result from extensive thrombosis of venules and capillaries within subcutaneous fat 1. This explains why areas rich in adipose tissue (breasts, buttocks, thighs) are most commonly affected 2. The mechanism involves protein C depletion, though it can occur even without protein C deficiency 1.
Critical Timing
Most cases become clinically manifest between the 3rd and 6th day of anticoagulant treatment 7, 1, though late presentations have been reported (one case at 46 days 6 and even after 15 years 2).
Management Implications
Immediate discontinuation of acenocoumarol is essential when these painful, erythematous, well-demarcated lesions appear 2. Early lesions may be reversible with prompt drug withdrawal 2, but established necrosis requires wound care and the lesions can take 6-14 months to resolve 8.
Key Clinical Pitfall
Do not dismiss early pain and erythema as minor reactions—these are warning signs of impending necrosis. The presence of pain with clear demarcation and surrounding erythema should trigger immediate evaluation for coumarin-induced skin necrosis 3.
If future anticoagulation is required, acenocoumarol is contraindicated. Restart with a different anticoagulant class (such as direct oral anticoagulants) or, if a vitamin K antagonist must be used, restart at very low doses (2 mg) under full therapeutic heparinization, increasing gradually over weeks 1.